What are the recommended antisickness (antiemetic) medicines during the first trimester of pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Antisickness Medicines in First Trimester

Start with vitamin B6 (pyridoxine) 10-25 mg every 8 hours as first-line pharmacological treatment, escalate to doxylamine-pyridoxine combination if symptoms persist, then use metoclopramide as the preferred second-line agent, and reserve ondansetron only for refractory cases with careful counseling about small but measurable risks of cardiac and orofacial malformations when used before 10 weeks gestation. 1, 2

Stepwise Treatment Algorithm

Non-Pharmacological First Steps

  • Implement dietary modifications: small, frequent, bland meals (BRAT diet: bananas, rice, applesauce, toast), high-protein and low-fat foods, while avoiding spicy, fatty, acidic, and fried foods 1, 2
  • Apply lifestyle changes: identify and avoid specific triggers, separate solid and liquid intake, and avoid an empty stomach 1, 2
  • Consider ginger 250 mg capsules four times daily as a safe and effective option for mild symptoms 2

First-Line Pharmacological Treatment

  • Vitamin B6 (pyridoxine) 10-25 mg orally every 8 hours is the initial pharmacological intervention, with demonstrated efficacy in improving symptoms according to PUQE and Rhode's scores 1, 2
  • If pyridoxine alone is insufficient, escalate to doxylamine-pyridoxine combination (10 mg/10 mg delayed-release), which is FDA pregnancy category A and recommended as first-line pharmacologic therapy by ACOG 1, 3

Second-Line Pharmacological Treatment

  • Metoclopramide 5-10 mg orally every 6-8 hours is the preferred second-line agent with an excellent safety profile 1, 2
  • A meta-analysis of six cohort studies involving 33,000 first-trimester exposures demonstrated no significant increase in risk of major congenital defects (odds ratio 1.14,99% CI 0.93-1.38) 2
  • Metoclopramide can be used safely throughout pregnancy, including for migraine-associated nausea 1
  • Important caveat: Administer intravenous doses by slow bolus injection over at least 3 minutes to minimize extrapyramidal effects 4

Third-Line Treatment (Refractory Cases)

  • Ondansetron should be used only when first-line and second-line treatments fail, with case-by-case consideration before 10 weeks gestation 5, 1
  • Ondansetron carries a small but measurable risk: 0.03% absolute increase in cleft palate and 0.3% absolute increase in ventricular septal defects 2
  • ACOG recommends using ondansetron on a case-by-case basis in patients with persistent symptoms before 10 weeks of pregnancy, balancing the very small increase in absolute risk of orofacial clefting against the risks of poorly managed hyperemesis gravidarum 5, 4

Severe Cases Requiring Hospitalization (Hyperemesis Gravidarum)

Inpatient Management

  • Provide IV hydration with normal saline (0.9% NaCl) with additional potassium chloride, guided by daily electrolyte monitoring 4
  • Administer thiamine supplementation 100 mg daily for minimum 7 days, followed by maintenance dosage of 50 mg daily until adequate oral intake is established, to prevent Wernicke encephalopathy and refeeding syndrome 5, 2
  • Use combination antiemetics from different drug classes (e.g., metoclopramide plus ondansetron) for better efficacy than single agents 5

Last Resort Treatment

  • Methylprednisolone 16 mg IV every 8 hours for up to 3 days, followed by tapering over 2 weeks, can be given as a last resort in severe hyperemesis gravidarum and reduces rehospitalization rates 5
  • Critical warning: Corticosteroids should be avoided before 10 weeks gestation due to slightly increased risk of cleft palate, though data have been conflicting 5, 2

Critical Clinical Pearls

Assessment and Monitoring

  • Use the PUQE score to quantify severity and guide treatment intensity: mild (≤6), moderate (7-12), severe (≥13) 1, 2
  • Early intervention prevents progression to hyperemesis gravidarum, which affects 0.3-2% of pregnancies and is characterized by intractable vomiting, dehydration, weight loss >5% of prepregnancy weight, and electrolyte imbalances 1, 2
  • Most nausea and vomiting begins at 4-6 weeks, peaks at 8-12 weeks, and subsides by week 20 2

Medications to Avoid

  • Never use methotrexate at any stage of pregnancy due to severe teratogenic effects 5
  • Avoid older-generation alkylating agents (procarbazine, busulfan), thalidomide, lenalidomide, pomalidomide, and tretinoin during pregnancy 5
  • Sodium valproate is contraindicated due to known teratogenic effects 1, 2
  • Topiramate and candesartan are associated with fetal adverse effects and must be avoided 1, 2

Common Pitfalls

  • Do not use ketonuria as an indicator of dehydration or to assess severity 4
  • Preventing nausea and vomiting is much easier than treating it once established; therefore, consider around-the-clock administration of antiemetics rather than PRN dosing for moderate to severe cases 5
  • If extrapyramidal effects occur with metoclopramide or phenothiazines, promptly discontinue the medication 5, 4

References

Guideline

Management of Nausea and Vomiting in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of First Trimester Nausea and Vomiting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The pharmacologic management of nausea and vomiting of pregnancy.

The Journal of family practice, 2014

Research

The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69).

BJOG : an international journal of obstetrics and gynaecology, 2024

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.